NateraNTRA
NTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 3,293
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more call options, than puts
Call options by funds: $43.1M | Put options by funds: $24.7M
27% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 52
14% more capital invested
Capital invested by funds: $13.4B [Q2] → $15.3B (+$1.85B) [Q3]
3% more funds holding
Funds holding: 472 [Q2] → 486 (+14) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 176 | Existing positions reduced: 193
3.68% less ownership
Funds ownership: 100.89% [Q2] → 97.21% (-3.68%) [Q3]
4% less funds holding in top 10
Funds holding in top 10: 25 [Q2] → 24 (-1) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
17%
downside
Avg. target
$166
2%
upside
High target
$200
24%
upside
10 analyst ratings
10 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Julia Qin 80% 1-year accuracy 4 / 5 met price target | 24%upside $200 | Overweight Maintained | 13 Dec 2024 |
Piper Sandler David Westenberg 69% 1-year accuracy 27 / 39 met price target | 24%upside $200 | Overweight Maintained | 18 Nov 2024 |
Morgan Stanley Tejas Savant 33% 1-year accuracy 4 / 12 met price target | 9%upside $176 | Overweight Maintained | 14 Nov 2024 |
TD Cowen Dan Brennan 48% 1-year accuracy 14 / 29 met price target | 8%upside $175 | Buy Maintained | 13 Nov 2024 |
Craig-Hallum Alexander Nowak 64% 1-year accuracy 9 / 14 met price target | 3%downside $157 | Buy Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 14 articles about NTRA published over the past 30 days
Positive
The Motley Fool
2 hours ago
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Billionaire Stanley Druckenmiller might not be a household name like Warren Buffett, but he's one of the best investors of all time.
Positive
Benzinga
23 hours ago
Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%
Billionaire Stanley Druckenmiller, a former confidant of George Soros and the founder of Duquesne Capital, built his career off making large, measured bets. His latest large wager has paid off.
Positive
Zacks Investment Research
4 days ago
Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Natera (NTRA) could be a good stock pick from a technical perspective. NTRA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Neutral
Business Wire
4 days ago
Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests. On December 10, 2024, the District Court for the Middle District of North Carolina (“The District Court”) granted Natera's request to include an additional patent in its ongoing lawsuit against NeoGenomics. Natera's amended complaint now includes U.S. Paten.
Neutral
Business Wire
1 week ago
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinical trial designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients wit.
Neutral
Business Wire
1 week ago
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer risk, offers individuals who receive a negative test result with Natera's Empower hereditary cancer test the opportunity.
Neutral
Business Wire
2 weeks ago
Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company's clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT). Natera's study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 65.
Neutral
Business Wire
3 weeks ago
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients in the surveillance setting. SLT patients make up ~20% of all U.S. lung transplants1. These patients are at an increase.
Neutral
Business Wire
3 weeks ago
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts. “We are proud to share this new data on Signatera at SABCS that underscores our commitment to generating evidence on the clinical utility of Signatera for patient.
Neutral
PRNewsWire
3 weeks ago
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO ALTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District Court for the Northern District of California (the "Court") unanimously found in favor of Guardant Health on all of its claims from its May 2021 lawsuit against Natera, Inc. (Nasdaq: NTRA) ("Natera") for false advertising and unfair competition.
Charts implemented using Lightweight Charts™